Analyst Price Target is $96.30
▲ +46.55% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Catalent in the last 3 months. The average price target is $96.30, with a high forecast of $145.00 and a low forecast of $78.00. The average price target represents a 46.55% upside from the last price of $65.71.
Current Consensus is
Buy
The current consensus among 9 polled investment analysts is to buy stock in Catalent. This Buy consensus rating has held steady for over two years.
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory manag
Read More
